drugset / Trial / NCT00288691

Menorrhagia Study in Women With Treatment-resistant Menorrhagia

NCT00288691

Phase 2 Completed 26 enrolled Bayer TAP Pharmaceutical Products Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to explore effects of the investigational product for the treatment of treatment-resistant menorrhagia without organic cause.

Timeline

Start
2001-11
Primary completion
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Asoprisnil Other / unclassified 5 mg Oral
Subject Asoprisnil Other / unclassified 10 mg Oral
Subject Asoprisnil Other / unclassified 25 mg Oral

Indications